Build status - In Progress

A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety Tolerability and Pharmacokinetics of BIIB105 Administered Intrathecally to Adults With Amyotrophic Lateral Sclerosis With or Without Poly-CAG Expansion in the Ataxin-2 Gene

Recruiting
99 years or below
All
1 Location

Brief description of study

This is a first in human, phase 1 trial of BIIB105, which is a novel ASO, in patients with Amyotrophic lateral sclerosis (ALS) and ALS associated with ataxin-2 (ATXN2) poly-CAG expansion (polyQ-ALS). BIIB105 will be administered via fluoro-guided LP up to 5 times over approximately 3 months. Subjects will undergo blood draws, physical examination, pulmonary and strength testing and will complete questionnaires. PolyQ-ALS (Cohort D2) must complete a Natural History Run-in Period prior to dosing.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 11 May 2022. Study ID: 843811

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center